SmithKline Beecham to Resale 2.475M Shares of Idenix Pharma (IDIX)
Up)
In a Form S-3 filed after the close yesterday, Idenix Pharma (Nasdaq: IDIX) disclosed a resale of 2,475,728 shares of common stock held by SmithKline Beecham Corporation, doing business as GlaxoSmithKline, that were issued by Idenix Pharmaceuticals, Inc. in a private placement completed on March 18, 2009.
Idenix said it wont receive any proceeds from the sale.
Idenix said it wont receive any proceeds from the sale.
You May Also Be Interested In
- Brean Murray Sees Recent Upside in Idenix (IDIX) Related to Possible Gilead (GILD) Settlement in June
- Socket Mobile (SCKT) Receives Non-Compliance Notification From NASDAQ
- Icahn's Letter to the Chesapeake (CHK) Board: Says Directors Failed to Oversee, Hold Management Accountable
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
